


Xellia Pharmaceuticals



Integrating
science and
innovation to
save lives

Xellia Pharmaceuticals is a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Based on our long-term expertise, we bring value to our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of, integrating science and knowledge to save lives.

Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics' sector.

Xellia is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). Our success and strong market position is built on more than 100 years' of pharmaceutical industry experience.

Xellia Pharmaceuticals' focus its R&D


investments within inhalable and injectable product technologies as we are committed to researching solutions, which not only improve patients' quality of life, but will also ultimately save lives.

Supplying products to more than 70 countries worldwide and with more than 500 customers internationally, Xellia Pharmaceuticals places a high regard on maintaining strong relationships with its customers.

Our sales team serves as the first point of contact for customers, ensuring fast and accurate delivery of product information;

through managing orders to delivery. Xellia Pharmaceuticals' Global Technical Support team serves as the main point of contact for customers to provide them with specialized support for all technical matters that may be associated with market entry and launch of products.

Working collaboratively with the sales team and cross-functionally with Xellia's internal departments at all sites, Xellia Pharmaceuticals is dedicated to providing reliable outstanding service to its customers at all times.



Active Pharmaceutical Ingredients and Finished Dosage Forms

APIs

Amphotericin B
Bacitracin
Bacitracin Zinc
Colistimethate Sodium
Colistin Sulfate
Daptomycin
Gramicidin
Polymyxin B Sulfate
Tobramycin Sulfate
Tyrothricin
Vancomycin Hydrochloride

FDFs

Bacitracin vials 50.000 units
Colistimethate Sodium dry-filled vials 1 miu, 2 miu
Colistimethate Sodium lyophilized vials 150mg
Daptomycin vials 350mg, 500mg
Polymyxin B vials 500.000 units
Vancomycin HCl Capsules 125mg, 250mg
Vancomycin HCl vials 0.5g, 1g, 5g, 10g
Voriconazole vials 200mg

*Products protected by valid patents are not offered
for sale in countries where the sale of such products
constitutes a patent infringement*

INTERNATIONAL SALES OFFICE: Xellia Pharmaceuticals ApS, Copenhagen, Denmark
Tel: [+45 32 64 55 00](tel:+4532645500) E-mail: sales@xellia.com

LOCAL SALES OFFICES AND GLOBAL TECHNICAL SUPPORT:
www.xellia.com/contact

A company owned by Novo Holdings A/S
www.xellia.com

